Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth. by Cohen, I. et al.
Br. J. Cancer (1994), 69, 620-621 © Macmillan Press Ltd., 1994
LETTER TO THE EDITOR
Tamoxifen treatment in premenopausal breast cancer patients may be
associated with ovarian overstimulation, cystic formations and fibroid
overgrowth
Sir - Tamoxifen is known to be effective adjuvant therapy
for breast cancer in pre- and post-menopausal patients with
positive oestrogen receptor proteins (Early Breast Trialists'
Collaborative Group, 1992). Chronic treatment with tamox-
ifen in premenopausal women with primary breast cancer has
been reported as causing an increase in ovarian oestrogen
synthesis in premenopausal women (Radvin et al., 1988), but
to the best of our knowledge only two case reports (Jolles et
al., 1990; Barbeiri et al., 1993) have mentioned mor-
phological changes of ovaries. Herein, we report on such
morphological changes, detected by vaginal ultrasound, in
our premenopausal breast cancer patients receiving tamox-
ifen, as well as in those patients who had stopped treatment.
We surveyed all the premenopausal breast cancer patients
in our hospital. Five patients were treated with 20-30 mg of
tamoxifen daily (ABIC Chemical and Pharmaceutical Indus-
tries, Netanya, Israel) for a period of 6-18 months
(mean ± s.d. 11.33 ± 6.11 months). Five other similar
patients were not receiving tamoxifen. None of the patients
had received any hormonal treatment. All patients had
gynaecological examinations, vaginal ultrasounds and hor-
monal serum level assessments.
Vaginal ultrasonographic evaluations revealed normal uteri
and ovaries among all the non-treated patients, whereas all
five of the tamoxifen-treated patients had persistent, bilateral
ovarian simple cysts of 5 x 7 cm in diameter. The premeno-
pausal breast cancer patients described herein produced enor-
mous amounts of oestrogens as a result of the action of the
tamoxifen. These oestrogen levels (1305-3765 pmol 1-1) were
much higher than those of similar patients unexposed to
tamoxifen (126-871 pmol 1'). The oestrogen levels were
found to be persistently much higher throughout the various
phases of the menstrual cycles.
Two patients had normal uteri, while three had fibroid
uteri, which grew progressively throughout the follow-up
period. Two patients had undergone total abdominal
hysterectomies and bilateral salpingo-oophorectomies, because
of cystic findings. Histological examination of the patients
showed bilateral, simple (functional) ovarian cysts and
enlarged, benign fibroid uteri, with thick proliferative
endometrium. Tamoxifen treatment was discontinued in a
third patient, in whom a gradual reduction in the size of the
ovarian cysts occurred until they completely disappeared 2
months later, with a concomitant decrease in oestradiol
levels. Two patients are still under supervision.
Although we describe only five such patients, we believe
that they represent a significant finding, since to the best of
our knowledge such a phenomenon has not yet been
reported. Furthermore, as none of the non-tamoxifen
patients developed such pathological morphological gyn-
aecological changes, this may indicate that similar findings
could be anticipated in most of the premenopausal breast
cancer patients being treated with tamoxifen. In three other
patients, now under our supervision, similar findings have
been observed. Moreover, the pharmacokinetic mechanism of
tamoxifen on the ovaries is well understood (Sawka et al.,
1986; Spicer et al., 1991), and therefore we may expect to
frequently find ovarian cyst formation in these patients.
The formation of such ovarian cysts may cause complica-
tions such as torsion (Barbeiri et al., 1993) and cystic necrosis
(Jolles et al., 1990). Permanent ovarian cysts may pose a
diagnostic dilemma, because ovarian enlargement in such
patients may also result from metastases of the primary
breast cancer. It has also been claimed that long-term tamox-
ifen treatment during premenopause might potentially in-
crease the risk of ovarian cancer (Spicer et al., 1991).
Three patients also demonstrated a rapid and progressive
growth of their fibroid uteri, a phenomenon which has only
recently been described (Dilts et al., 1992). This growth may
cause severe haemorrhagic menstrual bleeding, as happened
to one of our patients who underwent three consecutive
therapeutic curettages.
We have concluded that: (1) all premenopausal breast
cancer patients being treated with tamoxifen should- be under
close gynaecological and ultrasonographic surveillance and
(2) our observation has assumed more relevance and urgency
because several clinicil trials of tamoxifen chemoprophylaxis
are under way (Powles et al., 1989; National Surgical
Adjuvant Breast and Bowel Project P1, 1992).
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